CareDx, Inc 10-Qquarter ended 2026-06-30

Executive Summary

CareDx earns revenue from transplant-monitoring tests for clinicians and patients, laboratory products, and patient and digital services for transplant care. It is exiting laboratory products and expanding into specialty-oncology testing through Naveris while continuing to develop its transplant portfolio. Testing demand strengthened, but revenue growth also benefited materially from collections on older tests, and a business-sale gain accounted for almost all reported operating profit. Favorable transplant coverage supports adoption; investors must judge whether recurring testing economics and oncology expansion can deliver sustained profitability.

What's Happening in the Business

CareDx sold its laboratory-products business to Eurobio on 6/30/2026 for $172M in cash consideration, subject to adjustments. It then acquired Naveris on 7/1/2026 for $162M cash, with up to $100M more tied to FY2026 and FY2027 revenue milestones. The transactions redirect resources from kitted laboratory products toward testing and services. Naveris adds NavDx and entry into cancer residual-disease and recurrence monitoring, but requires integration in a market outside CareDx’s historical transplant focus.

The existing transplant business is expanding. Q2 testing volume reached ≈58,000, up 17% Y/Y, matching H1’s growth pace. Revenue grew much faster than volume because collections on previously performed tests boosted recognized revenue; the headline growth rate therefore does not measure new demand alone.

A final MolDX/Noridian coverage determination issued in 7/2026 affirmed coverage for kidney, heart and lung transplant tests, including surveillance and for-cause testing, subject to criteria. It is expected to take effect on 8/30/2026, supporting access without eliminating payment disputes.

Legal uncertainty narrowed but did not disappear. The Justice Department and SEC investigations ended without adverse findings or enforcement recommendations, and the related private whistleblower case was dismissed. Natera’s appeal of an overturned jury verdict remains unresolved.

Key Financial Highlights

Figures are rounded; comparisons are Y/Y.

• Testing collections: Revenue from earlier-period tests contributed $18.0M in Q2 and $35.6M in H1. Refund-reserve increases reduced revenue by $2.4M and $5.8M, respectively, showing how payer outcomes affect reported growth.
• Cost economics: Q2 testing costs rose only 3% as laboratory efficiencies absorbed higher volume. Patient and digital costs rose 78% to $14.7M, principally from pharmacy costs, limiting that category’s profit contribution.
• Investment: Q2 R&D rose 33% to $22.4M, sales and marketing 38% to $33.4M, and general and administrative expense 48% to $40.9M. Clinical development, commercialization, personnel, legal and consulting costs absorbed much of the gross-profit improvement.
• Liquidity: Cash reached $374M, with no debt, before the Naveris payment. Combined cash and marketable securities rose 86% from year-end, substantially supported by divestiture proceeds.
• Capital allocation: H1 repurchases were $12.2M vs $50.0M, yet shares outstanding increased 1.1% as equity issuance exceeded buybacks. H1 stock-based compensation was $20.5M, up 11%; a new $100M repurchase authorization remained unused.

Risk Assessment

• Reimbursement and collection: Medicare supplied 30% of Q2 revenue, while private-payer disputes and prior-test adjustments expose revenue and cash receipts to denials, recoupments and coverage changes.
• Oncology execution: Naveris consumes a substantial share of available cash and adds contingent payments; unsuccessful integration or commercialization could leave CareDx with higher costs and impaired acquired assets.
• Transplant dependence: CareDx expects its existing transplant portfolio to underpin revenue for at least two years; biopsy practices and competing tests could constrain adoption or pricing.
• Litigation: Natera’s appeal could reinstate a loss of up to $96.3M plus interest, despite the verdict’s reversal.
• Laboratory continuity: Testing sites are not fully redundant, and sole-source supplies and specialized operations make disruptions difficult to offset.

What to Watch

• Transplant demand and collections: Volume is growing 17%; sustained volume growth and dependable reimbursement would validate expansion, while weaker demand or adverse payer adjustments would undermine it.
• Naveris commercialization: NavDx brings Medicare coverage and oncology capabilities. Later filings should show whether acquired testing grows or instead requires retrenchment or write-downs.
• Recurring profitability: Operating profit excluding the sale gain was barely positive. The test is whether testing efficiencies can outpace clinical and commercial spending without relying on divestitures or unusually favorable older-test collections.